English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Is serum beta 2-microglobulin a tumor marker in gastrointestinal cancer?

MPS-Authors
/persons/resource/persons285242

Staab,  H-J
Anderer Group, Friedrich Miescher Laboratory, Max Planck Society;

/persons/resource/persons282624

Anderer,  FA
Anderer Group, Friedrich Miescher Laboratory, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Staab, H.-J., Anderer, F., Hiesche, K., Wehrle, E., & Rodatz, W. (1980). Is serum beta 2-microglobulin a tumor marker in gastrointestinal cancer? Clinica Chimica Acta (Amsterdam), 106(3), 309-317. doi:10.1016/0009-8981(80)90315-0.


Cite as: https://hdl.handle.net/21.11116/0000-000F-50BD-2
Abstract
Serial determinations of serum beta 2-microglobulin (beta 2m) and carcinoembryogenic antigen (CEA) were performed in 314 patients with histologically confirmed gastrointestinal cancer. The data were correlated with a set of clinical parameters. Pre-operative serum beta 2m levels did not discriminate different classes of tumor extension nor different stages of resectability of tumors in contrast to CEA. During post-operative surveillance the correlation of the time courses of serum beta 2m and CEA with the clinical course of malignant disease was studied in a selected group of 165 patients with resected primary carcinoma of the gastrointestinal tract. During the follow-up 74/165 patients showed disease progression or recurrence. In the beta 2m follow-up 66% false negative indications (49/74) of malignant disease were observed, whereas in the CEA follow-up it was 5% (4/74). The ratio of correct positive/false positive indications was 25/10 in the beta 2m follow-up and 70/10 in the CEA follow-up. The data indicate that the formation of serum beta 2m is not directly tumor associated in gastrointestinal cancer.